Drug intelligence / Profile preview

recombinant human DEL-1

Development stage
Preclinical
Lead developer
Del-1 Therapeutics
Modality
Recombinant Proteins and Enzymes
Administration
Local Injection, Topical
01

Overview

DEL-1 (Developmental Endothelial Locus-1), also known as EDIL3, is a secreted glycoprotein that serves as an endogenous anti-inflammatory factor. It functions primarily by regulating leukocyte recruitment, specifically by antagonizing the adhesion of neutrophils to the vascular endothelium. DEL-1 acts as a gatekeeper of the inflammatory response by binding to the integrin alpha-V beta-3 on endothelial cells, which prevents the interaction between the leukocyte integrin LFA-1 and its ligand ICAM-1. Additionally, DEL-1 can directly interact with LFA-1 on neutrophils to inhibit their activation and recruitment. Recombinant forms of DEL-1 are being investigated as therapeutic agents for inflammatory and autoimmune conditions, including periodontitis and multiple sclerosis, where the protein's ability to promote the resolution of inflammation and prevent tissue destruction is of high clinical interest.

Other names
Developmental Endothelial Locus-1EGF-like repeats and discoidin I-like domains 3
02

Targets

αVβ3 (Integrin αVβ3)LFA-1 (Integrin αLβ2)

Beyond the preview

Go deeper on recombinant human DEL-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human DEL-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call